X4 Pharmaceuticals, Inc (XFOR): EBITDA
-$85.61M
Year ended 2025-12-31
-$86.24M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$85.61M | n/m | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | -$35.60M | n/m | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | -$107.10M | n/m | 2026-03-17, From 2023-01-01 |
| 2022-12-31 | -$87.06M | n/m | 2025-03-26, From 2022-01-01 |
| 2021-12-31 | -$84.61M | n/m | 2024-03-21, From 2021-01-01 |
| 2020-12-31 | -$59.52M | n/m | 2023-03-21, From 2020-01-01 |
| 2019-12-31 | -$51.60M | n/m | 2022-03-17, From 2019-01-01 |
| 2018-12-31 | -$28.98M | n/m | 2021-03-19, From 2018-01-01 |
| 2017-12-31 | -$22.18M | n/c | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | -$24.06M | n/a | 2019-03-11, From 2016-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | -$85.61M | n/m |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | -$113.26M | n/m |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | -$50.68M | n/m |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | -$341.09M | n/m |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | -$117.28M | n/m |
| Scilex Holding Co (SCLX) | 2025-12-31 | -$341.38M | n/m |
| Alector, Inc. (ALEC) | 2025-12-31 | -$150.29M | n/m |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $237.0K | -96.2% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | -$90.85M | n/m |
Compare XFOR, CCCC, DTIL, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗